Global Anti-Platelet Agents Market Is Forecasted To Expand At A Cagr Of 7% By 2033 X Herald

(MENAFN- Ameliorate Digital Consultancy) The global anti-platelet agents market is valued at US$ 2.4 billion in 2023 and is forecasted to expand at a CAGR of 7% during the study period of 2023 to 2033. As such, global demand for anti-platelet agents is projected to reach a market valuation of US$ 4.8 billion by the end of 2033.

Rising cardiovascular issues are further estimated to fuel demand for anti-platelet agents to ensure effective healthcare solutions for people. These anti-platelet agents prevent clotting by restricting the activity of the platelet to bind or stick together. Furthermore, clotting of blood is generally a physiological reaction of the human body that assists in controlling any sort of external bleeding at the time of injury.

For more insights into the Market, Request a Sample of this Report:

Key Takeaways from Market Study:

  • The global anti-platelet agents market is anticipated to reach a valuation of US$ 4.8 billion by 2033-end.
  • Sales of anti-platelet agents in Canada are predicted to advance at a CAGR of 6.2% through 2033.
  • The size of the global market is US$ 2.4 billion in the year 2023.
  • Demand for anti-platelet agents in Germany is forecasted to increase at a CAGR of 4.4% from 2033.
  • The global market is estimated to progress at a noteworthy CAGR of 7% through 2033.

“Rising cases of cardiovascular diseases and growing research & development activities to develop anti-platelet agents are estimated to lead to lucrative opportunities for market players,” says a Fact.MR analyst.

Anti-platelet agents are more efficient for arterial clots. These clots are made largely of platelets. Anti-platelet agents can avoid clot formation and prevent platelets from clumping. Varimedications to achieve this effect act on proteins and receptors that receive chemical signals and can cause cells to bind. Further, anti-platelet agents are generally used as a first-line antithrombotic therapy to manage acute ischemic syndromes while preventing their recurrence.

For example, aspirin is used to block thromboxane, which is a blood-clotting chemical. The medicine is sold under multiple brand names, including Easprin, Bayer, Aspir, and Ecotrin. Aspirin is commonly prescribed to people who are experiencing a heart attack as it can rapidly and effectively inhibit the growth of blood clots and platelet activity and thelps to maintain some measure of blood flow.

Competitive landscape:

Industry players are investing at a significant rate in new developments. These players are concentrating to strengthen the supply chain management system and providing quality products to end users. In the respective manufacturing process, they adhere to imposed rules and regulations that are set for quality control of end products and causing minimal environmental impacts.

These players are adopting numerstrategies, including merger & acquisition, approvals, partnerships, and others to generate untapped opportunities.

For instance :

  • Alfasigma in June 2021 announced that it has received approval for the European license, which was for bentracimab from PhaseBio. Further, Bentracimab is a new human monoclonal antibody fragment. It has been designed for the reversal of the anti-platelet effects of Brilique/Brillinta in clinical tests.

Key suppliers of anti-platelet agents are Aspen, The Medicines Company, Sanofi, Pfizer, Johnson & Johnson, Daiichi Sankyo, Bristol-Myers Squibb, and Otsuka.

Segmentation of Anti-Platelet Agents Industry Research

· By Drug :

  • Aspirin
  • Clopidogrel
  • Ticagrelor
  • Prasugrel
  • Others

· By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

· By Application :

  • Angioplasty
  • PercutaneCoronary Interventions
  • Myocardial Infraction
  • Dental Surgeries
  • Arterial Thrombosis

· By End User :

  • Ambulatory Surgical Centers
  • Hospitals
  • Emergency Service Centers
  • Clinics

· By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

For in-depth competitive analysis, Buy Now:

Questionnaire answered in the Market outlook Report of Anti-Platelet Agents include:

  • What is the key strategy deployed by large players to maximize Anti-Platelet Agents Market growth?
  • What are the main challenges faced by players in the Anti-Platelet Agents market Demand?
  • With the advent of technological advancement, how will the Anti-Platelet Agents market landscape change over the forecast period?
  • What does player bring to the table which is unique as a strategy, and is easy to emulate for new investors in the Anti-Platelet Agents market size?

Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.